[HTML][HTML] OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing …
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant, R Relator… - Frontiers in Cell and …, 2022 - hal.science
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant… - Frontiers in Cell …, 2022 - univ-rennes.hal.science
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
[HTML][HTML] OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing …
E Colin, Y Duffourd, E Tisserant, R Relator… - Frontiers in Cell and …, 2022 - ncbi.nlm.nih.gov
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant, R Relator… - Frontiers in Cell and …, 2022 - europepmc.org
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant, R Relator… - Frontiers in Cell and …, 2022 - cnrs.hal.science
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant… - Frontiers in Cell …, 2022 - u-bourgogne.hal.science
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant, R Relator, AL Bruel… - 2022 - agris.fao.org
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant… - Frontiers in cell …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results …
E Colin, Y Duffourd, E Tisserant, R Relator… - Frontiers in Cell and …, 2022 - europepmc.org
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …
worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an …